GO:0061754 negative regulation of circulating fibrinogen levels: Coagulation Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061754 describes any biological process that reduces the amount of fibrinogen circulating in the bloodstream.
• Fibrinogen is a key coagulation protein; its circulating levels are tightly linked to inflammatory and thrombotic states.
• Dysregulated fibrinogen levels are observed in conditions such as aortic dissection, abdominal aortic aneurysm, and malignancies.
• The process is regulated by a balance of synthesis, secretion, consumption, and clearance mechanisms, with inflammatory cytokines and coagulation factors playing major roles.
• Research models for this process include knockout, knock-in, and overexpression cell lines, as well as CRISPR library screening.
• Understanding negative regulation of circulating fibrinogen levels is critical for developing therapies for thrombotic and inflammatory diseases.
Description
Fibrinogen is a soluble plasma glycoprotein that serves as the precursor to fibrin, the structural backbone of blood clots. Its circulating concentration is a critical determinant of blood viscosity, platelet aggregation, and clot formation. The Gene Ontology term GO:0061754, negative regulation of circulating fibrinogen levels, encompasses any process that reduces the quantity of fibrinogen in the bloodstream. This regulation is essential for maintaining hemostatic balance and preventing pathological thrombosis or bleeding. Dysregulation of fibrinogen levels is associated with a wide range of human diseases, including acute aortic dissection, abdominal aortic aneurysm, and various malignancies. Therefore, understanding the molecular mechanisms that negatively regulate circulating fibrinogen is of significant clinical and research interest. This article synthesizes current knowledge from authoritative QuickGO annotations and verified PubMed literature to provide a comprehensive overview of the term, its biological significance, and experimental approaches for its study.
negative regulation of circulating fibrinogen levels At A Glance
| GO ID | GO:0061754 |
|---|---|
| GO term | negative regulation of circulating fibrinogen levels |
| Ontology | biological_process |
| Synonym | none |
| Major function | Reduction of fibrinogen concentration in the bloodstream |
| Related processes | Coagulation, inflammation, acute-phase response |
| Key regulators | Inflammatory cytokines, coagulation factors, hepatic function |
| Disease relevance | Thrombosis, aortic dissection, abdominal aortic aneurysm, cancer |
What Is GO:0061754?
GO:0061754, negative regulation of circulating fibrinogen levels, is defined as any process that reduces the quantity of fibrinogen circulating in the bloodstream. This biological process can occur through multiple mechanisms, including decreased hepatic synthesis, increased consumption during coagulation, enhanced clearance by the liver or reticuloendothelial system, or altered secretion from hepatocytes. The term captures the net effect of these processes on the concentration of fibrinogen in plasma, which is a key biomarker and functional component of the coagulation cascade.
Why Is negative regulation of circulating fibrinogen levels Important in Cell Biology?
The negative regulation of circulating fibrinogen levels is crucial for preventing excessive clot formation and maintaining vascular homeostasis. Elevated fibrinogen is a well-established risk factor for cardiovascular events, and its reduction can be protective in thrombotic disorders. Conversely, impaired negative regulation may contribute to hypercoagulable states observed in inflammatory diseases and malignancies. Understanding this process provides insights into the pathophysiology of diseases such as aortic dissection and abdominal aortic aneurysm, where fibrinogen and other circulating biomarkers are altered. Moreover, targeting the pathways that negatively regulate fibrinogen could offer therapeutic strategies for managing thrombotic risk.
• Prevents pathological thrombosis by limiting fibrinogen availability for clot formation.
• Modulates blood viscosity and flow dynamics.
• Influences inflammatory responses through fibrinogen-derived peptides.
• Serves as a biomarker for acute aortic dissection and other vascular emergencies.
• Associated with prognosis in various malignancies.
• Plays a role in abdominal aortic aneurysm pathogenesis.
• Impacts wound healing and tissue repair processes.
• Regulated by hepatic acute-phase response and cytokines.
• Potential target for anticoagulant therapies.
• Relevant to aging and metabolic disorders.
What Happens During negative regulation of circulating fibrinogen levels?
Decreased Hepatic Synthesis
In simple terms: The liver makes less fibrinogen, so less gets into the blood.
Fibrinogen is primarily synthesized in hepatocytes. Negative regulation can occur at the transcriptional level, where inflammatory cytokines such as interleukin-6 (IL-6) can either stimulate or, under certain conditions, suppress fibrinogen gene expression. For example, in acute-phase responses, IL-6 typically increases fibrinogen production, but negative feedback mechanisms or anti-inflammatory signals can reduce synthesis. Additionally, hepatic dysfunction or damage can lead to decreased fibrinogen production, lowering circulating levels.
Increased Consumption During Coagulation
In simple terms: Fibrinogen is used up quickly to form clots, so less remains in the blood.
During activation of the coagulation cascade, thrombin cleaves fibrinogen to form fibrin. In conditions of excessive coagulation, such as disseminated intravascular coagulation (DIC), fibrinogen is consumed faster than it can be replaced, leading to reduced circulating levels. This consumption is a direct mechanism of negative regulation, as the protein is removed from circulation through incorporation into clots.
Enhanced Clearance
In simple terms: The body removes fibrinogen from the blood more quickly.
Fibrinogen can be cleared from circulation by the liver and reticuloendothelial system. Enhanced clearance may occur via receptor-mediated endocytosis or through binding to specific proteins that facilitate its removal. For instance, the asialoglycoprotein receptor on hepatocytes can recognize desialylated fibrinogen and mediate its uptake and degradation. This pathway represents a direct negative regulatory mechanism.
Inflammatory and Cytokine Modulation
In simple terms: Inflammation can change how much fibrinogen is in the blood.
Inflammatory mediators can influence fibrinogen levels both positively and negatively. While IL-6 is a major inducer of fibrinogen synthesis, other cytokines such as interleukin-10 (IL-10) or transforming growth factor-beta (TGF-beta) may suppress its production. In the context of malignancies, plasma levels of phospholipase A2-IIA correlate with coagulation biomarkers, suggesting a link between inflammation and fibrinogen regulation. The interleukin-33/soluble ST2 axis has also been implicated in adipose tissue inflammation and may indirectly affect fibrinogen levels.
Genetic and Epigenetic Regulation
In simple terms: Genes can be turned on or off to control fibrinogen levels.
Polymorphisms in the fibrinogen genes (FGA, FGB, FGG) can affect circulating levels. Epigenetic modifications, such as DNA methylation and histone acetylation, can also regulate fibrinogen gene expression. For example, sirtuin 1 (SIRT1), a histone deacetylase, has been shown to increase after fat loss in obese patients, and may influence hepatic gene expression programs. These genetic and epigenetic factors contribute to inter-individual variability in fibrinogen levels and the capacity for negative regulation.
Key Genes Involved in GO:0061754 negative regulation of circulating fibrinogen levels
The following genes and proteins are involved in the regulation of circulating fibrinogen levels, either as direct components of the coagulation system or as regulators of its synthesis and clearance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGA | Encodes fibrinogen alpha chain | Mutations cause dysfibrinogenemia; target for knockout studies |
| FGB | Encodes fibrinogen beta chain | Polymorphisms affect plasma fibrinogen levels |
| FGG | Encodes fibrinogen gamma chain | Alternative splicing produces gamma prime variant with altered function |
| F2 | Encodes prothrombin (thrombin precursor) | Thrombin cleaves fibrinogen; key regulator of consumption |
| IL6 | Pro-inflammatory cytokine | Induces fibrinogen synthesis; negative regulators may counteract |
| IL10 | Anti-inflammatory cytokine | May suppress fibrinogen production |
| TGFB1 | Transforming growth factor beta 1 | Inhibits fibrinogen synthesis in hepatocytes |
| SERPINC1 | Antithrombin III | Inhibits thrombin, indirectly reducing fibrinogen consumption |
| PLA2G2A | Phospholipase A2 group IIA | Correlates with coagulation biomarkers in malignancies |
| SIRT1 | Sirtuin 1 | Influences hepatic gene expression; increases after fat loss |
| IL33 | Interleukin 33 | Regulates inflammation; may affect fibrinogen indirectly |
| IL1RL1 | ST2 receptor for IL-33 | Soluble ST2 is a biomarker for aortic dissection |
| MMP9 | Matrix metalloproteinase 9 | Involved in aortic aneurysm; may influence fibrinogen |
| ELN | Elastin | Component of aortic wall; degraded in aneurysm |
| FBN1 | Fibrillin 1 | Mutations cause Marfan syndrome; associated with aortic dissection |
| COL3A1 | Collagen type III alpha 1 | Vascular integrity; mutations in Ehlers-Danlos syndrome |
| APOA1 | Apolipoprotein A1 | Plasma protein identified in abdominal aortic aneurysm proteomics |
How Is negative regulation of circulating fibrinogen levels Regulated?
The negative regulation of circulating fibrinogen levels is controlled by a complex network of transcriptional, post-transcriptional, and post-translational mechanisms. In hepatocytes, the expression of fibrinogen genes (FGA, FGB, FGG) is regulated by transcription factors such as C/EBP and HNF-1, which respond to inflammatory cytokines like IL-6. Anti-inflammatory signals, including IL-10 and TGF-beta, can suppress fibrinogen synthesis. At the post-translational level, thrombin-mediated cleavage and subsequent fibrin formation consume fibrinogen, while clearance receptors mediate its removal. Additionally, epigenetic modifiers such as SIRT1 may influence hepatic gene expression programs. The interleukin-33/ST2 axis has been implicated in adipose tissue inflammation and may indirectly modulate fibrinogen levels. Overall, the balance between synthesis and removal determines the circulating concentration.
negative regulation of circulating fibrinogen levels and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGA | Dysfibrinogenemia, thrombosis | Knockout hepatocyte cell line |
| IL1RL1 | Acute aortic dissection | Overexpression of soluble ST2 in vascular cells |
| PLA2G2A | Malignancy-associated thrombosis | Knockdown in cancer cell lines |
| SIRT1 | Obesity, metabolic syndrome | Knock-in of SIRT1 in hepatocytes |
| MMP9 | Abdominal aortic aneurysm | Knockout in smooth muscle cells |
Aortic Dissection
Acute aortic dissection is a life-threatening vascular emergency. Circulating levels of soluble ST2 have been identified as a novel biomarker for acute aortic dissection, and fibrinogen levels are often altered in this condition. Negative regulation of fibrinogen may be disrupted, contributing to thrombotic complications. Research into the molecular mechanisms could improve diagnostic and therapeutic approaches.
Abdominal Aortic Aneurysm
Abdominal aortic aneurysm (AAA) is characterized by progressive dilation of the aorta. Proteomic analysis of plasma from AAA patients has identified alterations in several proteins, including fibrinogen and apolipoprotein A1. Dysregulated fibrinogen levels may contribute to thrombus formation within the aneurysm sac. Understanding negative regulation could provide insights into AAA pathogenesis.
Malignancies
Cancer patients often exhibit hypercoagulability and elevated fibrinogen levels. Plasma levels of phospholipase A2-IIA correlate with inflammatory and coagulation biomarkers in patients with different types of malignancies. Negative regulation of fibrinogen may be impaired, promoting tumor-associated thrombosis. Targeting this process could reduce thrombotic risk in cancer patients.
Obesity and Metabolic Disorders
Obesity is associated with chronic inflammation and altered fibrinogen levels. Circulating SIRT1 increases after intragastric balloon fat loss in obese patients, suggesting a link between metabolic status and hepatic gene regulation. The interleukin-33/ST2 axis plays a context-dependent role in obesity and adipose tissue inflammation, potentially influencing fibrinogen. Negative regulation of fibrinogen may be relevant to metabolic syndrome.
From negative regulation of circulating fibrinogen levels-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate fibrinogen secretion? | CRISPR knockout of gene X in HepG2 cells |
| Does a point mutation in FGA affect fibrinogen clearance? | Point mutation knock-in in iPSC-derived hepatocytes |
| Can overexpression of IL10 reduce fibrinogen levels? | Overexpression of IL10 in primary hepatocytes |
| What is the role of SIRT1 in hepatic fibrinogen synthesis? | Knock-in of tagged SIRT1 for ChIP-seq |
| Does soluble ST2 modulate fibrinogen in aortic dissection? | Overexpression of IL1RL1 in vascular smooth muscle cells |
| Which genes regulate fibrinogen levels in cancer? | CRISPR library screening in cancer cell lines |
How to Study the negative regulation of circulating fibrinogen levels Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Fibrinogen concentration | Quantify secreted fibrinogen from hepatocytes |
| Mass spectrometry | Plasma protein profile | Discover biomarkers in AAA |
| RNA-seq | Gene expression changes | Identify transcriptional regulators |
| ChIP-seq | Histone modifications and TF binding | Study epigenetic regulation |
| CRISPR screen | Gene function on a genome-wide scale | Identify negative regulators |
| Thrombin time assay | Functional fibrinogen | Assess coagulation capacity |
| Immunohistochemistry | Tissue protein localization | Detect fibrinogen in liver or vessels |
| Flow cytometry | Cell surface markers | Analyze endothelial progenitor cells |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss alters circulating fibrinogen levels. For example, knocking out candidate genes in hepatocyte cell lines followed by ELISA for fibrinogen in the supernatant can reveal negative regulators. This approach is unbiased and scalable.
Proteomics and Biomarker Discovery
Proteomic approaches, such as mass spectrometry, can identify plasma proteins associated with fibrinogen regulation. In abdominal aortic aneurysm, proteomic analysis revealed alterations in fibrinogen and other proteins. These methods are useful for discovering novel biomarkers and pathways.
Transcriptomics and Epigenomics
RNA-seq and ChIP-seq can reveal transcriptional and epigenetic changes in fibrinogen genes under conditions that reduce circulating levels. For instance, SIRT1-mediated histone deacetylation may repress fibrinogen gene expression. These techniques provide mechanistic insights.
Functional Assays
Coagulation assays, such as thrombin time and fibrinogen antigen assays, directly measure fibrinogen levels and function. These are essential for validating findings from genetic and pharmacological studies. They can be applied to cell culture supernatants and plasma samples.
How CRISPR Can Be Used to Study GO:0061754 negative regulation of circulating fibrinogen levels
Knockout
CRISPR knockout of candidate genes in hepatocyte cell lines (e.g., HepG2) can determine whether the gene is required for maintaining or reducing fibrinogen levels. For example, knocking out a putative negative regulator should lead to increased fibrinogen secretion, which can be measured by ELISA. This approach provides causal evidence.
Point Mutation
Introducing point mutations in fibrinogen genes (FGA, FGB, FGG) can mimic human polymorphisms associated with altered fibrinogen levels. For instance, a point mutation in the FGB promoter may affect transcription factor binding and reduce synthesis. These models are valuable for studying genetic regulation.
Knock-in
Knock-in of tagged proteins (e.g., GFP-SIRT1) allows for live-cell imaging and chromatin immunoprecipitation to study dynamic regulation of fibrinogen genes. Knock-in of disease-associated mutations can also model human conditions.
Overexpression
Overexpression of anti-inflammatory cytokines such as IL10 or of soluble ST2 can test their ability to reduce fibrinogen levels in vitro and in vivo. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports negative regulation of circulating fibrinogen levels Research
Researchers studying negative regulation of circulating fibrinogen levels-related genes often need to determine whether a candidate gene is causally involved in reducing fibrinogen concentration. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides a comprehensive suite of services to support such investigations, from custom cell line generation to high-throughput screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of circulating fibrinogen levels research.
Frequently Asked Questions About negative regulation of circulating fibrinogen levels
What is GO:0061754?
GO:0061754 is a Gene Ontology term for negative regulation of circulating fibrinogen levels, defined as any process that reduces the quantity of fibrinogen in the bloodstream.
What genes are involved in negative regulation of circulating fibrinogen levels?
Key genes include FGA, FGB, FGG (fibrinogen chains), F2 (thrombin), IL6, IL10, TGFB1, and SIRT1, among others.
How is circulating fibrinogen level regulated?
It is regulated by a balance of hepatic synthesis, consumption during coagulation, and clearance from the blood, influenced by inflammatory cytokines and genetic factors.
Why is fibrinogen level important in disease?
Elevated fibrinogen is a risk factor for thrombosis and cardiovascular diseases, while low levels can cause bleeding; it is also a biomarker for aortic dissection and cancer.
What diseases are associated with abnormal fibrinogen levels?
Aortic dissection, abdominal aortic aneurysm, malignancies, and obesity-related metabolic disorders are associated with altered fibrinogen levels.
How can I study negative regulation of fibrinogen levels in the lab?
You can use CRISPR knockout, point mutation, knock-in, or overexpression cell models, combined with ELISA, proteomics, and coagulation assays.
What is the role of SIRT1 in fibrinogen regulation?
SIRT1, a histone deacetylase, may influence hepatic gene expression and has been shown to increase after fat loss in obese patients, potentially affecting fibrinogen synthesis.
Is soluble ST2 a biomarker for aortic dissection?
Yes, soluble ST2 has been identified as a novel biomarker for acute aortic dissection, and it may relate to fibrinogen regulation.
What is the link between inflammation and fibrinogen levels?
Inflammatory cytokines like IL-6 can increase fibrinogen synthesis, while anti-inflammatory signals such as IL-10 may suppress it, thereby negatively regulating circulating levels.
What CRISPR services are available for studying fibrinogen regulation?
EDITGENE offers knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services to study fibrinogen regulation.
Conclusion
The negative regulation of circulating fibrinogen levels (GO:0061754) is a critical biological process that maintains hemostatic balance and prevents thrombotic disorders. Dysregulation of this process is implicated in aortic dissection, abdominal aortic aneurysm, malignancies, and metabolic diseases. Advances in CRISPR-based gene editing and high-throughput screening have enabled researchers to dissect the molecular players involved, from fibrinogen genes to inflammatory cytokines and epigenetic modifiers. Continued research in this area promises to uncover new therapeutic targets for thrombotic and inflammatory conditions.
References
- 1. Bateman RM et al.. 2016. 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.. Crit Care 20(Suppl 2):94 PMID: 27885969
- 2. Wang Y et al.. 2018. Magnitude of Soluble ST2 as a Novel Biomarker for Acute Aortic Dissection.. Circulation 137(3):259-269 PMID: 29146682
- 3. O'Toole TE et al.. 2010. Episodic exposure to fine particulate air pollution decreases circulating levels of endothelial progenitor cells.. Circ Res 107(2):200-3 PMID: 20595651
- 4. Nedić O et al.. 2017. Analysis of Four Circulating Complexes of Insulin-Like Growth Factor Binding Proteins in Human Blood during Aging.. Biochemistry (Mosc) 82(10):1200-1206 PMID: 29037141
- 5. Casado M et al.. 2026. Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation.. Mol Med 32(1) PMID: 41814156
- 6. Menschikowski M et al.. 2013. Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.. Pathol Oncol Res 19(4):839-46 PMID: 23722320
- 7. Mariani S et al.. 2016. Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients.. Obes Surg 26(6):1215-20 PMID: 26337692
- 8. Gamberi T et al.. 2011. A proteomic approach to identify plasma proteins in patients with abdominal aortic aneurysm.. Mol Biosyst 7(10):2855-62 PMID: 21805001
